4//SEC Filing
SWARTZ ERIC S 4
Accession 0001683168-17-002243
CIK 0000704562other
Filed
Aug 28, 8:00 PM ET
Accepted
Aug 29, 5:16 PM ET
Size
8.5 KB
Accession
0001683168-17-002243
Insider Transaction Report
Form 4
SWARTZ ERIC S
Director
Transactions
- Other
Stock Option (right to buy)
2017-08-25−15,966→ 258,247 totalExercise: $9.17Exp: 2025-05-11→ Common Stock (15,966 underlying) - Other
Stock Option (right to buy)
2017-08-25−4,706→ 253,541 totalExercise: $3.50Exp: 2026-06-02→ Common Stock (4,706 underlying)
Footnotes (3)
- [F1]Pursuant to the settlement terms of a derivative lawsuit approved by Vice Chancellor Laster by Order dated July 27, 2017 (the "Settlement Date"), Mr. Swartz has agreed to an annual compensation cap for a period of two years from the Settlement Date. Although not required, on August 25, 2017, Mr. Swartz voluntarily surrendered for cancelation and for no consideration, 15,966 options (originally granted on May 11, 2015) and 4,706 options (originally granted on June 2, 2016), which reduced his total annual compensation for fiscal years 2016 and 2017 to below the agreed upon cap.
- [F2]The underlying option grant provided for vesting in eight (8) equal quarterly installments over a two (2) year period beginning August 11, 2015 and each quarter thereafter until fully-vested.
- [F3]The underlying option grant provided for vesting in eight (8) equal quarterly installments over a two (2) year period beginning September 2, 2016 and each quarter thereafter until fully-vested.
Documents
Issuer
PEREGRINE PHARMACEUTICALS INC
CIK 0000704562
Entity typeother
Related Parties
1- filerCIK 0001244108
Filing Metadata
- Form type
- 4
- Filed
- Aug 28, 8:00 PM ET
- Accepted
- Aug 29, 5:16 PM ET
- Size
- 8.5 KB